Michael H. Davidson insider trades

Open-market stock purchases and sales by Michael H. Davidson, Chief Executive Officer at NewAmsterdam Pharma Co NV, from SEC Form 4 filings since Apr 16, 2013.

Track record: 50% of 4 scored buys are up 5% or more since purchase, averaging -3%.

Recent trades

DateStockTradeValue
Sep 14, 2026NAMS NewAmsterdam Pharma Co NVBought$227K
Jun 10, 2026BIOA BioAge Labs, IncBought (not open market)—
Mar 2, 2026NAMS NewAmsterdam Pharma Co NVSold$14.8M
Mar 2, 2026NAMS NewAmsterdam Pharma Co NVBought (not open market)—
Feb 26, 2026NAMS NewAmsterdam Pharma Co NVSold$617K
Feb 26, 2026NAMS NewAmsterdam Pharma Co NVBought (not open market)—
Feb 26, 2026NAMS NewAmsterdam Pharma Co NVSold$5.6M
Feb 25, 2026NAMS NewAmsterdam Pharma Co NVBought (not open market)—
Feb 25, 2026NAMS NewAmsterdam Pharma Co NVSold$1.6M
Feb 25, 2026NAMS NewAmsterdam Pharma Co NVSold$375K
Feb 25, 2026NAMS NewAmsterdam Pharma Co NVSold$47.7K
Feb 24, 2026NAMS NewAmsterdam Pharma Co NVSold$2.2M
Feb 24, 2026NAMS NewAmsterdam Pharma Co NVSold$115K
Feb 24, 2026NAMS NewAmsterdam Pharma Co NVBought (not open market)—
Jan 9, 2026TENX Tenax Therapeutics, IncBought (not open market)—
Jan 7, 2026NAMS NewAmsterdam Pharma Co NVSold—
Jan 7, 2026NAMS NewAmsterdam Pharma Co NVBought (not open market)—
Jan 7, 2026NAMS NewAmsterdam Pharma Co NVBought (not open market)—

Companies traded

  • NAMS NewAmsterdam Pharma Co NV: 3 buys, 10 sales, last Sep 14, 2026
  • BIOA BioAge Labs, Inc: other filings, last Jun 10, 2026
  • TENX Tenax Therapeutics, Inc: 3 buys, last Jan 9, 2026
  • SLN Silence Therapeutics plc: other filings, last Jan 2, 2025
  • CLBS Caladrius Biosciences, Inc: 1 buy, last Jan 10, 2022
  • OMTH Omthera Pharmaceuticals, Inc: other filings, last Jul 18, 2013

Get free alerts when Michael H. Davidson files a new trade →